Furthermore, IL-2 deprivation-mediated NK cell dysfunction was overcome by NKp30 overexpression, proposing NKp30 upregulation as a viable modality to harness NK cells in cancer immunotherapy. The gene discussed is NCR3; the disease is cancer.